The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

No­vo Nordisk’s once-a-day sick­le cell dis­ease drug etavopi­vat cut the rate of pain crises in a year­long mid-stage study.

In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis and to resolve steatohepatitis with no worsening of ...

Additional positive data presented in a late-breaker poster by Pentara and colleagues titled “Additional Analysis of a 52-Week Phase II Trial of Neuromodulation of the Default Mode Network to ...

Credit: Art_Photo via Shutterstock. A Phase II clinical trial evaluating Sinaptica Therapeutics’ neuromodulation device in Alzheimer’s disease has hit its primary and key secondary endpoints. The ...

Welcome to TechRadar's Marvel Phase 5 hub. In this article, you'll find the latest news and rumors on Marvel Cinematic Universe (MCU)'s current phase, which is due to end in July 2025. It's ...

"Prior to this paper, we had written a paper that observed a similar phase transition in entanglement, in which we had observed phases where measurements of a quantum system preserved or destroyed ...

However, minor differences in crystal oscillator frequencies among controllers may lead to pulse width modulation (PWM ... In response, our article proposes a carrier phase self-synchronization method ...